APEIRON Biologics

APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million 

Ligand also commits to invest up to USD 4 million in APEIRON spin-off, invIOs 8 July 2024, Vienna, Austria – APEIRON Biologics AG (“APEIRON”), a leading Austrian biotech company, today announced that its shareholders have entered into a definitive agreement to sell their APEIRON shares to US-based Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) for $100m. APEIRON shareholders...
Campus-Vienna-Biocenter 5, 1030 Vienna, Austria

+43 1 86565 77